Ghent University Academic Bibliography

Advanced

Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of Primary Irresectable Cervical Cancer

Katrien Vandecasteele UGent, Wilfried De Neve UGent, Werner De Gersem UGent, Louke Delrue UGent, LEEN PAELINCK UGent, Amin Makar UGent, Valérie Fonteyne UGent, Carlos De Wagter UGent, Geert Villeirs UGent and Gert De Meerleer UGent (2009) STRAHLENTHERAPIE UND ONKOLOGIE. 185(12). p.799-807
abstract
Purpose: To report on the planning procedure, quality control, and clinical implementation of intensity-modulated arc therapy (IMAT) delivering a simultaneous integrated boost (SIB) in patients with primary irresectable cervix carcinoma. Patients and Methods: Six patients underwent PET-CT (positron emission tomography-computed tomography) and MRI (magnetic resonance imaging) before treatment planning. Prescription (25 fractions) was (1) a median dose (D-50) of 62, 58 and 56 Gy to the primary tumor (GTV_cervix), primary clinical target volume (CTV_cervix) and its planning target volume (PTV_cervix), respectively; (2) a D-50 of 60 Gy to the PET-positive Lymph nodes (GTV_nodes); (3) a minimal dose (D-98) of 45 Gy to the planning target volume of the elective lymph nodes (PTV_nodes). IMAT plans were generated using an anatomy-based exclusion toot with the aid of weight and leaf position optimization. The dosimetric delivery of IMAT was validated prectinically using radiochromic film dosimetry. Results: Five to nine arcs were needed to create valid IMAT plans. Dose constraints on D-50 were not met in two patients (both GTV_cervix: 1 Gy and 3 Gy less). D-98 for PTV_nodes was not met in three patients (1 Gy each). Film dosimetry showed excellent gamma evaluation. There were no treatment interruptions. Conclusion: IMAT allows delivering an SIB to the macroscopic tumor without compromising the dose to the elective lymph nodes or the organs at risk. The clinical implementation is feasible.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
journal title
STRAHLENTHERAPIE UND ONKOLOGIE
Strahlenther. Onkol.
volume
185
issue
12
pages
799 - 807
Web of Science id
000272525100004
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
3.776 (2009)
JCR rank
12/104 (2009)
JCR quartile
1 (2009)
ISSN
0179-7158
DOI
10.1007/s00066-009-1986-8
language
English
UGent publication?
yes
classification
A1
id
817826
handle
http://hdl.handle.net/1854/LU-817826
date created
2010-01-05 12:50:39
date last changed
2010-03-04 09:41:52
@article{817826,
  abstract     = {Purpose: To report on the planning procedure, quality control, and clinical implementation of intensity-modulated arc therapy (IMAT) delivering a simultaneous integrated boost (SIB) in patients with primary irresectable cervix carcinoma.

Patients and Methods: Six patients underwent PET-CT (positron emission tomography-computed tomography) and MRI (magnetic resonance imaging) before treatment planning. Prescription (25 fractions) was

(1) a median dose (D-50) of 62, 58 and 56 Gy to the primary tumor (GTV\_cervix), primary clinical target volume (CTV\_cervix) and its planning target volume (PTV\_cervix), respectively;

(2) a D-50 of 60 Gy to the PET-positive Lymph nodes (GTV\_nodes);

(3) a minimal dose (D-98) of 45 Gy to the planning target volume of the elective lymph nodes (PTV\_nodes).

IMAT plans were generated using an anatomy-based exclusion toot with the aid of weight and leaf position optimization. The dosimetric delivery of IMAT was validated prectinically using radiochromic film dosimetry.

Results: Five to nine arcs were needed to create valid IMAT plans. Dose constraints on D-50 were not met in two patients (both GTV\_cervix: 1 Gy and 3 Gy less). D-98 for PTV\_nodes was not met in three patients (1 Gy each). Film dosimetry showed excellent gamma evaluation. There were no treatment interruptions.

Conclusion: IMAT allows delivering an SIB to the macroscopic tumor without compromising the dose to the elective lymph nodes or the organs at risk. The clinical implementation is feasible.},
  author       = {Vandecasteele, Katrien and De Neve, Wilfried and De Gersem, Werner and Delrue, Louke and PAELINCK, LEEN and Makar, Amin and Fonteyne, Val{\'e}rie and De Wagter, Carlos and Villeirs, Geert and De Meerleer, Gert},
  issn         = {0179-7158},
  journal      = {STRAHLENTHERAPIE UND ONKOLOGIE},
  language     = {eng},
  number       = {12},
  pages        = {799--807},
  title        = {Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of Primary Irresectable Cervical Cancer},
  url          = {http://dx.doi.org/10.1007/s00066-009-1986-8},
  volume       = {185},
  year         = {2009},
}

Chicago
Vandecasteele, Katrien, Wilfried De Neve, Werner De Gersem, Louke Delrue, LEEN PAELINCK, Amin Makar, Valérie Fonteyne, Carlos De Wagter, Geert Villeirs, and Gert De Meerleer. 2009. “Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of Primary Irresectable Cervical Cancer.” Strahlentherapie Und Onkologie 185 (12): 799–807.
APA
Vandecasteele, Katrien, De Neve, W., De Gersem, W., Delrue, L., PAELINCK, L., Makar, A., Fonteyne, V., et al. (2009). Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of Primary Irresectable Cervical Cancer. STRAHLENTHERAPIE UND ONKOLOGIE, 185(12), 799–807.
Vancouver
1.
Vandecasteele K, De Neve W, De Gersem W, Delrue L, PAELINCK L, Makar A, et al. Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of Primary Irresectable Cervical Cancer. STRAHLENTHERAPIE UND ONKOLOGIE. 2009;185(12):799–807.
MLA
Vandecasteele, Katrien, Wilfried De Neve, Werner De Gersem, et al. “Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of Primary Irresectable Cervical Cancer.” STRAHLENTHERAPIE UND ONKOLOGIE 185.12 (2009): 799–807. Print.